Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2020-11-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고(보고)' (Amendment to Securities Registration Statement for Equity Securities) filed by UBiologics. It details specific amendments to a previously filed securities registration statement, including changes to share counts, investment risks, and major shareholder status. This falls under the category of regulatory filings related to capital raising and securities registration, which is best classified as a Regulatory Filing (RNS) as it is a formal amendment to a registration statement.
2020-11-11 Korean
[기재정정]투자설명서
Investor Presentation Classification · 95% confidence The document is a 'Correction Report' (정정신고) for an 'Investment Prospectus' (투자설명서). It details specific amendments to financial data, share counts, and risk factors following the exercise of stock warrants. In the context of Korean financial filings (DART), a 'Correction Report' for a prospectus is a regulatory filing that updates previously submitted offering documents. Since it is a formal amendment to a prospectus, it falls under the category of Regulatory Filings (RNS) as it does not fit into the specific categories of annual reports, earnings releases, or proxy statements.
2020-11-11 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고서' (Amendment to Securities Registration Statement) filed with the Financial Services Commission (금융위원회) in South Korea. It details changes to the issuance price and total offering amount for a capital increase (유상증자). This type of regulatory filing, which provides detailed information about a share issuance and capital structure change, falls under the 'Share Issue/Capital Change' category.
2020-11-11 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '정정신고(보고)' (Amendment Report) for an '투자설명서' (Prospectus) regarding a capital increase (유상증자). It details changes to the offering price, total offering amount, and use of proceeds. In the context of Korean regulatory filings (DART), this is a formal amendment to a securities registration statement, which falls under the category of capital and financing updates.
2020-11-11 Korean
권리락(유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding a 'rights offering' (유상증자) and the resulting 'ex-rights' (권리락) date for Eubiologics. It provides specific details on the stock code, reference price, and the reason for the adjustment. This fits the definition of a capital change announcement related to share issuance/capital structure adjustments.
2020-11-11 Korean
유상증자1차발행가액결정
Capital/Financing Update Classification · 100% confidence The document is an official announcement from Eubiologics regarding the determination of the first issue price for a paid-in capital increase (rights offering). It details the calculation methodology, the number of shares, and the pricing formula for the capital raise. This falls under the category of capital and financing updates.
2020-11-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.